J Drugs Dermatol. 2022 Oct 1;21(10):1133-1134.
Dermatomyositis (DM) is an autoimmune myopathy with characteristic dermatologic features.1 Tofacitinib is an immunomodulator with proven efficacy against numerous immune-mediated disorders, including rheumatoid arthritis (RA) and psoriasis.2 Several reports have demonstrated oral tofacitinib’s ability to treat the cutaneous and extracutaneous manifestations of refractory dermatomyositis (DM).1,4,5 However, evidence for sustained improvement remains limited.2,3 The goal of this study is to investigate the long-term response of recalcitrant DM to oral and topical tofacitinib at varied dosing regimens.
皮肌炎（DM）是一种自身免疫性肌病，具有特征性的皮肤表现。1 托法替尼是一种免疫调节剂，已被证明对多种免疫介导的疾病有效，包括类风湿关节炎（RA）和银屑病。2 多项报告表明，口服托法替尼能够治疗难治性皮肌炎（DM）的皮肤和皮肤外表现。1,4,5 然而，持续改善的证据仍然有限。2,3 本研究的目的是研究不同剂量方案的口服和局部应用托法替尼对难治性 DM 的长期反应。
